Vast Therapeutics Announces Series A Funding
Partnership with Shionogi Ltd Includes Collaboration for Development of Proprietary Nitric Oxide Powder Technology for Antimicrobial Resistant Bacteria in Respiratory Applications
DURHAM, N.C., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Venture Capital Vast Therapeutics, KNOW Bio, nitric oxide, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cystic Fibrosis | Funding | Marketing | Partnerships | Respiratory Medicine | Venture Capital